Lars Møller Pedersen

6.6k total citations · 1 hit paper
103 papers, 3.4k citations indexed

About

Lars Møller Pedersen is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Lars Møller Pedersen has authored 103 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pathology and Forensic Medicine, 35 papers in Genetics and 35 papers in Oncology. Recurrent topics in Lars Møller Pedersen's work include Lymphoma Diagnosis and Treatment (60 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Viral-associated cancers and disorders (19 papers). Lars Møller Pedersen is often cited by papers focused on Lymphoma Diagnosis and Treatment (60 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Viral-associated cancers and disorders (19 papers). Lars Møller Pedersen collaborates with scholars based in Denmark, Sweden and United States. Lars Møller Pedersen's co-authors include Nils Milman, Ole Gadeberg, Francesco d’Amore, Michael Møller, Martin Hutchings, A. M. Boesen, Susanne Keiding, Annika Loft, Lena Specht and Mads Hansen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lars Møller Pedersen

92 papers receiving 3.3k citations

Hit Papers

Immunohistochemical Double-Hit Score Is a Strong Predicto... 2012 2026 2016 2021 2012 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
    2012 481 citations Ole Gadeberg, Mikael Frederiksen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Møller Pedersen Denmark 28 2.1k 1.4k 972 705 586 103 3.4k
Paul A. Hamlin United States 33 2.9k 1.4× 2.0k 1.5× 925 1.0× 431 0.6× 521 0.9× 155 4.0k
John Sweetenham United States 34 2.8k 1.3× 2.0k 1.5× 1.5k 1.5× 385 0.5× 468 0.8× 143 4.6k
Matthew J. Matasar United States 32 2.7k 1.3× 2.4k 1.7× 923 0.9× 567 0.8× 353 0.6× 190 3.9k
Ralph Naumann Germany 21 1.6k 0.7× 986 0.7× 405 0.4× 819 1.2× 588 1.0× 52 2.9k
Paul Hoskins Canada 37 2.4k 1.1× 2.2k 1.6× 757 0.8× 247 0.4× 582 1.0× 131 5.5k
José Thomas Belgium 38 3.3k 1.5× 1.5k 1.1× 1.1k 1.1× 785 1.1× 1.2k 2.1× 77 4.3k
Paolo G. Gobbi Italy 29 1.6k 0.7× 905 0.7× 686 0.7× 238 0.3× 497 0.8× 86 2.6k
Hervé Ghesquières France 31 2.1k 1.0× 1.6k 1.1× 852 0.9× 211 0.3× 274 0.5× 193 3.0k
Simon Rule United Kingdom 30 2.4k 1.1× 1.7k 1.2× 1.6k 1.6× 220 0.3× 404 0.7× 155 3.4k
Tina Nielsen Switzerland 28 1.2k 0.6× 912 0.7× 498 0.5× 332 0.5× 450 0.8× 114 2.4k

Countries citing papers authored by Lars Møller Pedersen

Since Specialization
Citations

This map shows the geographic impact of Lars Møller Pedersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Møller Pedersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Møller Pedersen more than expected).

Fields of papers citing papers by Lars Møller Pedersen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Møller Pedersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Møller Pedersen. The network helps show where Lars Møller Pedersen may publish in the future.

Co-authorship network of co-authors of Lars Møller Pedersen

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Møller Pedersen. A scholar is included among the top collaborators of Lars Møller Pedersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Møller Pedersen. Lars Møller Pedersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pedersen, Lars Møller, et al.. (2025). A Collaborative Online International Learning (COIL) Experience in Early Childhood Teacher Education. Education Sciences. 15(4). 494–494. 1 indexed citations
3.
Jensen, Paw, Peter de Nully Brown, Pär Josefsson, et al.. (2025). Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting. European Journal Of Haematology. 114(5). 832–839.
4.
5.
Schejbel, Lone, Anne Ortved Gang, Ib Jarle Christensen, et al.. (2024). TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma. European Journal Of Haematology. 114(3). 573–579. 1 indexed citations
6.
Nielsen, Torsten Holm, Ditte Stampe Hersby, Simon Østergaard, et al.. (2024). Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study. Blood Advances. 9(4). 893–905.
7.
Hersby, Ditte Stampe, Mary Jarden, Torsten Holm Nielsen, et al.. (2024). Sexual health and testosterone concentration in male lymphoma survivors: A systematic review. Heliyon. 10(11). e31915–e31915. 1 indexed citations
8.
Nielsen, Torsten Holm, et al.. (2023). Men treated with BEACOPP for Hodgkin lymphoma may be at increased risk of testosterone deficiency. Annals of Hematology. 103(1). 227–239.
9.
Hersby, Ditte Stampe, Lone Schejbel, Estrid Høgdall, et al.. (2023). Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma. Leukemia & lymphoma. 64(9). 1527–1535. 4 indexed citations
10.
Østergaard, Simon, Lone Schejbel, Peter Nørgaard, et al.. (2022). Bone Involvement as a Primary Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report and Prevalence in a Nationwide Population-Based Cohort Study. Journal of Hematology. 11(6). 233–239. 2 indexed citations
11.
Itenov, Theis Skovsgaard, Rasmus Ehrenfried Berthelsen, Jens‐Ulrik Stæhr Jensen, et al.. (2018). Predicting recovery from acute kidney injury in critically ill patients: development and validation of a prediction model. Critical Care and Resuscitation. 20(1). 54–60. 14 indexed citations
12.
13.
Pedersen, Lars Møller, et al.. (2014). Analgesic effect of ultrasound‐guided transversus abdominis plane block after total abdominal hysterectomy: a randomized, double‐blind, placebo‐controlled trial. Acta Obstetricia Et Gynecologica Scandinavica. 94(3). 274–278. 17 indexed citations
14.
Johnsen, Hans Erik, Carsten Geisler, Eeva Juvonen, et al.. (2010). Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment. Bone Marrow Transplantation. 46(1). 44–51. 2 indexed citations
15.
Brown, Peter de Nully, Lars Møller Pedersen, Bjarne Bach Pedersen, et al.. (2008). Follicular lymphoma in young patients (>50 yrs): A population-based analysis of the Danish lymphoma registry. Annals of Oncology. 19. 176–176. 4 indexed citations
16.
d’Amore, Francesco, Peter de Nully Brown, Lars Møller Pedersen, et al.. (2008). Primary refractory disease in non-Hodgkin lymphoma (NHL): Occurence, clinico-pathological features, and outcome. Annals of Oncology. 19. 132–132. 1 indexed citations
17.
Coiffier, Bertrand, Stéphane Leprêtre, Lars Møller Pedersen, et al.. (2007). Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 111(3). 1094–1100. 287 indexed citations
18.
Pedersen, Lars Møller & Olav J. Bergmann. (2003). Urinary Albumin Excretion and its Relationship to C-reactive Protein and Proinflammatory Cytokines in Patients with Cancer and Febrile Neutropenia. Scandinavian Journal of Infectious Diseases. 35(8). 491–494. 10 indexed citations
19.
Pedersen, Lars Møller & Nils Milman. (1996). Prognostic significance of thrombocytosis in patients with primary lung cancer. European Respiratory Journal. 9(9). 1826–1830. 198 indexed citations
20.
Pedersen, Lars Møller, Henrik Nordin, Henrik Nielsen, & Ida Maria Lisse. (1992). Non-Hodgkin malignant lymphoma in the nails in the course of a chronic lymphocytic leukaemia.. Acta Dermato Venereologica. 72(4). 277–278. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul A. Hamlin Breakdown of academic impact, for papers by John Sweetenham Breakdown of academic impact, for papers by Matthew J. Matasar Breakdown of academic impact, for papers by Ralph Naumann Breakdown of academic impact, for papers by Paul Hoskins Breakdown of academic impact, for papers by José Thomas Breakdown of academic impact, for papers by Paolo G. Gobbi Breakdown of academic impact, for papers by Hervé Ghesquières Breakdown of academic impact, for papers by Simon Rule Breakdown of academic impact, for papers by Tina Nielsen
Rankless by CCL
2026